Zeng, MA
Chenhui Zeng, Sudbury, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090054632 | Hydrophobically-modified protein compositions and methods - Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle. | 02-26-2009 |
Dingli Zeng, Wellesley, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20150120615 | UNIFIED CATALOG MANAGEMENT OF BUSINESS PRODUCTS AND SERVICES - A unified catalog of products and services is described. In one implementation, a method may include receiving an indication of products, offered by a business, that are to be provided to a customer of the business, where the products are defined in a catalog based on a hierarchical product model. The method further includes determining pricing information relating to the products, the determination of the pricing information including: identifying, based on the catalog, a plurality of pricing formulas associated with the plurality of products, and applying the pricing formulas to determine the pricing information. | 04-30-2015 |
Hansong Zeng, Acton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20150268237 | BIOASSAY SYSTEM AND METHOD FOR DETECTING ANALYTES IN BODY FLUIDS - A bioserisor platform is configured with upconverting nanoparticles on the surface of a resonant grating structure with enhanced sensitivity. The grating structure is illuminated with a light beam at one of its resonance modes to form a strong evanescent field at the surface and used for high sensitivity assays. The strong evanescent field triggers the upconverting nanoparticles to generate enhanced and localized emission on the grating surface, with lower background and lower auto-fluorescence from the grating substrate. This leads to improved performance in detecting analytes in bioassays. | 09-24-2015 |
Hongbo Zeng, Westford, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100130465 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS - The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. | 05-27-2010 |
| 20120114739 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS - The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds. | 05-10-2012 |
| 20120178744 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS - The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R | 07-12-2012 |
| 20120328691 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. | 12-27-2012 |
James Jin Xiong Zeng, Westwood, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090140694 | SEQUENCING SWITCHED SINGLE CAPACITOR FOR AUTOMATIC EQUALIZATION OF BATTERIES CONNECTED IN SERIES - Techniques for sequencing switched single capacitor for automatic equalization of batteries connected in series are described herein. In one embodiment, a battery equalizer includes a single capacitor, at least two switching circuits to be coupled to each of at least two batteries coupled in series. The battery equalizer further includes at least two driver circuits corresponding the at least two switching circuits and a controller. The controller is programmed to control the driver circuits in order to drive the switching circuits to sequentially couple the single capacitor to one of the batteries coupled in series during charging and/or discharging of the batteries. Only one of the switching circuits is turned on at a given time such that only one of the batteries is coupled to the single capacitor at the given time. Other methods and apparatuses are also described. | 06-04-2009 |
Jianyu Zeng, Reading, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100323665 | Method of Seamless Roaming Between Wireless Local Area Networks and Cellular Carrier Networks - A scheme that enables seamless roaming between the WLAN and the cellular carrier network by enabling a user that originates a call in the WLAN and happens to go outside the range of the WLAN to automatically switch over to the cellular carrier network without losing connection with the other party. This solution assumes that the mobile device has the capability to operate in at least two modes that include the WLAN mode and one of the cellular carrier modes, such as the GSM, IS-95 CDMA, IS-136 TDMA, and iDEN. | 12-23-2010 |
| 20120028646 | Method of Seamless Roaming Between Wireless Local Area Networks and Cellular Carrier Networks - A scheme that enables seamless roaming between the WLAN and the cellular carrier network by enabling a user that originates a call in the WLAN and happens to go outside the range of the WLAN to automatically switch over to the cellular carrier network without losing connection with the other party. This solution assumes that the mobile device has the capability to operate in at least two modes that include the WLAN mode and one of the cellular carrier modes, such as the GSM, IS-95 CDMA, IS-136 TDMA, and iDEN. | 02-02-2012 |
| 20130329697 | METHOD OF SEAMLESS ROAMING BETWEEN WIRELESS LOCAL AREA NETWORKS AND CELLULAR CARRIER NETWORKS - A scheme that enables seamless roaming between the WLAN and the cellular carrier network by enabling a user that originates a call in the WLAN and happens to go outside the range of the WLAN to automatically switch over to the cellular carrier network without losing connection with the other party. This solution assumes that the mobile device has the capability to operate in at least two modes that include the WLAN mode and one of the cellular carrier modes, such as the GSM, IS-95 CDMA, IS-136 TDMA, and iDEN. | 12-12-2013 |
Li Zeng, Framingham, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20140004047 | Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells | 01-02-2014 |
| 20140255364 | 3D CULTURE SYSTEM FOR CULTURING CELLS IN SYNOVIAL FLUID, CELLS CULTURED IN SYNOVIAL FLUID AND THEIR USE - Disclosed herein are materials and methods for culturing cells derived from joint cavities, said culturing being performed in the presence of synovial fluid. Also disclosed herein are cells cultured by the methods described herein, and their use for therapeutic purposes and for identifying therapeutic agents. | 09-11-2014 |
Ling Zeng, Brighton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20140335108 | UTILITY OF INSULIN-LIKE 6 (INSL6) FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis. | 11-13-2014 |
Ling Zeng, Boston, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090142336 | METABOLIC REGULATORS AND USES THEREOF - The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogenesis and cardiovascular function. In particular, the present invention relates to modulating metabolic function by administering an effective amount of a pharmaceutical composition comprising an agent, where the agent activates or inhibits the activity and/or gene expression of the metabolic regulator. The metabolic regulators of the present invention are, for example MSP1 (2160028F08Rik; SEQ ID NO: 16); MSP2 (2310043I08Rik; SEQ ID NO: 17); MSP3 (NM_026754;1 110017116Rik; SEQ ID NO: 1); MSP4 (4732466D17Rik; SEQ BD NO: 18); MSP 5 (NM_024237; 1600015H20Rik; SEQ ID NO: 12); Ins16 (AF_156094; SEQ ID NO: 20). The present invention also provides methods to screen for agents that affect the metabolic regulators of the present invention. | 06-04-2009 |
Qiandong Zeng, Waltham, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090017054 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides isolated polypeptide and nucleic acid sequences derived from | 01-15-2009 |
| 20090074806 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides isolated polypeptide and nucleic acid sequences derived from | 03-19-2009 |
| 20090148890 | Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics - The invention provides isolated polypeptide and nucleic acid sequences derived from | 06-11-2009 |
| 20090215149 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics - The invention provides isolated polypeptide and nucleic acid sequences derived from | 08-27-2009 |
| 20130078271 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS - The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection. | 03-28-2013 |
| 20140255443 | Nucleic Acid And Amino Acid Sequences Relating To Streptococcus Pneumoniae For Diagnostics And Therapeutics - The invention provides methods of treating subject with polypeptides having at least 80% identity to SEQ ID NO: 5326. The methods stimulate an immune response in the subject and provide methods for prevention and treatment of pathological conditions resulting from bacterial infection. | 09-11-2014 |
Qingfu Zeng, Hamilton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110195447 | Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-ALPHA - The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFRα) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFRα is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFRα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor. | 08-11-2011 |
Quingfu Zeng, Hamilton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20130266965 | Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-ALPHA - The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFRα) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFRα is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFRα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor. | 10-10-2013 |
Shengyou Zeng, Concord, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090125957 | STATEFUL DHCPv6 RELAY AGENT IN A CABLE MODEM TERMINATION SYSTEM - A CMTS or other data aggregation component having a DHCPv6 relay agent extracts a Media Access Control (MAC) address of an end device from a data packet received from an end device. A DHCPv6 data frame is created for transmission to a DHCPv6 server. The MAC address may be inserted into a specific option of the DHCPv6 data frame, where data in the option may not be processed by the server and are echoed back to the aggregation component or CMTS. The DHCPv6 data frame is transmitted to the DHCPv6 server. The component receives a response message from the server that may contain the MAC address or similar client hardware address as it was sent to the server by the network component. The network component may determine an outgoing port interface from which the response message should be sent, utilizing the MAC address and an interface bundling table. In this manner, interface bundling may be enabled. | 05-14-2009 |
| 20110066855 | AUTHENTICATION FOR DEVICES LOCATED IN CABLE NETWORKS - An extensible authentication framework is used in cable networks such as Data Over Cable Service Interface Specification (DOCSIS) cable networks. The authentication scheme allows for centralized authentication of cable modems, as well as authentication of the cable network by cable modems. Additionally, the authentication scheme allows a Cable Modem Termination System (CMTS) to authenticate devices downstream from cable modems, such as Customer Premise Equipment (CPE) devices. | 03-17-2011 |
Taofang Zeng, Cambridge, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120128958 | SILICA AEROGELS AND THEIR PREPARATION - Silica aerogels with improved properties are disclosed together with methods for synthesizing such aerogels. The improved properties include lower thermal conductivity (better insulating capacity), lower acoustic velocity, lower dielectric constant and improved ductility. Greater tunability of the refractive index can also be achieved. The silica aerogels are prepared by a sol-gel processing method that provides better control of the formation of aerogel structures. Generally speaking, the improvements arise from control of the synthesis to create a morphology of primary clusters and diverse-sized secondary clusters of dense silica aerogels separated by less densely packed regions. By providing a broader range of secondary clusters and/or pore sizes and loose connectivity between clusters, reductions can be achieved in thermal conductivity and flexural modulus. | 05-24-2012 |
Weifei Zeng, Cambridge, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20130195106 | Multi-Path Data Transfer Using Network Coding - Techniques, devices, systems, and protocols are disclosed herein that relate to data transfer between communication nodes via multiple heterogeneous paths. In various embodiments, network coding may he used to improve data flow and reliability in a multiple path scenario. Transmission control protocol (TCP) may also be used within different paths to further enhance data transfer reliability. In some embodiments, multiple levels of network coding may be provided within a transmitter in a multiple path scenario, with one level being applied across ail paths and another being applied within individual paths. | 08-01-2013 |
| 20140280454 | Method and Apparatus for Implementing Distributed Content Caching In A Content Delivery Network - Distributed content caching is implemented in an efficient, low cost manner within a content delivery network (CDN). In various embodiments, content is identified for caching at a number of gateway devices within a CDN by minimizing a cost function associated with content delivery in the network. The cost function may take into consideration costs of delivering content to users from gateway devices as well as costs associated with delivering content to users from centralized locations of a CDN. | 09-18-2014 |
Weike Zeng, Winchester, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120282245 | BIOMARKERS AND ASSAYS FOR THE TREATMENT OF CANCER - This invention features methods for prognosticating the efficacy of a cancer treatment comprising administration of a lymphotoxin-β receptor (LT-β-R) using TRAF3, TRAF2, and/or p53 markers, as well as combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other agents. | 11-08-2012 |
Xing Zeng, Jamaica Plain, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120115948 | INHIBITORS OF ANAPHASE PROMOTING COMPLEX ACTIVITY - The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibing the ubiquitination activity of the APC by administering compositions of the invention. | 05-10-2012 |
| 20130230458 | Cell Permeable Inhibitors of Anaphase Promoting Complex - The invention provides compositions and methods for treating cell cycle disorders. Compositions of the invention include proTAME, a prodrug analog of TAME, and, optionally, one or more therapeutic agents. | 09-05-2013 |
Yan Zeng, Cambridge, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090271330 | SYSTEM AND METHOD FOR PROVIDING THE EXECUTION PROBABILITY OF A LIMIT ORDER - A system, method and computer program product are described for providing the execution probability of a limit order within a given time period based on historical and current information and for adaptively and dynamically adjusting to intra-day trade data. For a given financial interest, the frequency of trade execution, the time evolution of the price, the time evolution of the trade volume, and the current state of the market, among other parameters, are captured and/or calculated. A probability function is generated based on the parameters corresponding to various time spans, and the execution probability of a limit order within a given time period is provided. Embodiments of the invention can be employed to estimate the probability of a limit order being executed within a given time period in the future, e.g., the next two minutes, based on the parameter data of a given time period in the past, e.g., the previous five minutes. | 10-29-2009 |
Yichong Zeng, Chelmsford, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20110089861 | Mechanical Interface For Glass Bulb For Use in Solid State Light Source Retrofit Lamps - A mechanical interface for a glass bulb is provided. The mechanical interface includes a connector and an optical mount. The connector is in contact with the glass bulb. The connector may be a separate component attached to the glass bulb, or may be a continuous part of the glass bulb, such that the connector is itself made of glass. The optical mount is configured to receive the connector. In so receiving, the optical mount operatively couples with the connector so as to secure the glass bulb in a position. The optical mount is also configured to attach to a lamp housing. A solid state light source retrofit lamp may thus be formed of a lamp housing including a solid state light source light engine and its required components, a glass bulb, and a mechanical interface for the glass bulb. | 04-21-2011 |
| 20130068439 | Heat Sink Assembly - A heat sink assembly ( | 03-21-2013 |
| 20130070454 | Modular Light Emitting Diode (LED) Lamp - An LED lamp ( | 03-21-2013 |
| 20130242557 | Heat Sink Assembly and Light - A heat sink for a light emitting diode (LED) lamp assembly includes a core region having a lower end, an upper end, a first region configured to receive an electrical connector, a second region configured to receive at least one LED, and a plurality of longitudinal vanes extending outwardly from the core region, and an upper thermal ring intersecting with and supported by the vanes. The heat sink further includes webs formed between adjacent pairs of the longitudinal vanes, the webs collectively defining an auxiliary thermal ring, the auxiliary thermal ring substantially circumferentially surrounding in spaced relation the core region and disposed, as viewed in the longitudinal direction, between the upper thermal ring and the lower rim. Each of the longitudinal vanes defines a respective thermal notch formed on a vane surface facing an adjacent longitudinal vane, the thermal notch being in confronting relationship to a respective air low aperture. | 09-19-2013 |